{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:03:53Z","timestamp":1761919433807},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1603,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1111\/j.1600-0463.2011.02744.x","type":"journal-article","created":{"date-parts":[[2011,4,12]],"date-time":"2011-04-12T10:44:35Z","timestamp":1302605075000},"page":"336-346","source":"Crossref","is-referenced-by-count":27,"title":["Differential patterns of spinal cord pathology induced by MP4, MOG peptide 35-55, and PLP peptide 178-191 in C57BL\/6 mice"],"prefix":"10.1111","volume":"119","author":[{"given":"STEFANIE","family":"KUERTEN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TRAUGOTT L.","family":"GRUPPE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LAURA-MARIA","family":"LAURENTIUS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHRISTIANE","family":"KIRCH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MAGDALENA","family":"TARY-LEHMANN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PAUL V.","family":"LEHMANN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KLAUS","family":"ADDICKS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,4,12]]},"reference":[{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.23.021704.115707","article-title":"Immunology of multiple sclerosis","volume":"23","author":"Sospedra","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/brain\/awl075","article-title":"Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70\u2003years of merits and culprits in experimental autoimmune encephalomyelitis research","volume":"129","author":"Gold","year":"2006","journal-title":"Brain"},{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1750-3639.2007.00064.x","article-title":"The immunopathology of multiple sclerosis: an overview","volume":"17","author":"Lassmann","year":"2007","journal-title":"Brain Pathol"},{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"8083","DOI":"10.1073\/pnas.0903377106","article-title":"The gray matter aspects of white matter disease in multiple sclerosis","volume":"106","author":"Steinman","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ana.21640","article-title":"The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?","volume":"65","author":"Weiner","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB6|cit6","first-page":"482","article-title":"Rodent models of experimental allergic encephalomyelitis applied to the study of multiple sclerosis","volume":"46","author":"Goverman","year":"1996","journal-title":"Lab Anim Sci"},{"issue":"Suppl 6","key":"10.1111\/j.1600-0463.2011.02744.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00415-008-6003-0","article-title":"Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations","volume":"255","author":"Mix","year":"2008","journal-title":"J Neurol"},{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/eji.200939568","article-title":"EAE: an immunologist\u2019s magic eye","volume":"39","author":"Krishnamoorthy","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1744-313X.1976.tb00583.x","article-title":"Experimental autoimmune encephalomyelitis in mice - genetic control of susceptibility","volume":"3","author":"Bernard","year":"1976","journal-title":"J Immunogenet"},{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/BF02115013","article-title":"Genetic control of resistance to clinical EAE accompanied by histological symptoms","volume":"31","author":"Gasser","year":"1990","journal-title":"Immunogenetics"},{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1002\/eji.1830250723","article-title":"A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells","volume":"25","author":"Mendel","year":"1995","journal-title":"Eur J Immunol"},{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s001090050092","article-title":"Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis","volume":"75","author":"Bernard","year":"1997","journal-title":"J Mol Med"},{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"462","DOI":"10.4049\/jimmunol.171.1.462","article-title":"Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL\/6 mice","volume":"171","author":"Oliver","year":"2003","journal-title":"J Immunol"},{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.4049\/jimmunol.168.8.4173","article-title":"De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis","volume":"168","author":"Tompkins","year":"2002","journal-title":"J Immunol"},{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB15|cit15","first-page":"4749","article-title":"MBP-PLP fusion protein-induced EAE in C57BL\/6 mice","volume":"178","author":"Kuerten","year":"2006","journal-title":"J Neuroimmunol"},{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.clim.2008.07.016","article-title":"Fundamental differences in the dynamics of CNS lesion development and composition in MP4-, and MOG peptide 35-55-inuced experimental autoimmune encephalomyelitis","volume":"129","author":"Kuerten","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood-2005-04-1496","article-title":"Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy","volume":"106","author":"Zappia","year":"2005","journal-title":"Blood"},{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jneuroim.2007.06.016","article-title":"MP4-, and MOG:35-55-induced EAE in C57BL\/6 mice differentially targets brain, spinal cord and cerebellum","volume":"189","author":"Kuerten","year":"2007","journal-title":"J Neuroimmunol"},{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.it.2004.01.007","article-title":"The CD4-Th1 model for multiple sclerosis: a critical re-appraisal","volume":"25","author":"Lassmann","year":"2004","journal-title":"Trends Immunol"},{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/brain\/awh550","article-title":"Motor neuron pathology in experimental autoimmune encephalomyelitis: studies in THY1-YFP transgenic mice","volume":"128","author":"Bannerman","year":"2005","journal-title":"Brain"},{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/ana.21436","article-title":"Gray matter atrophy in multiple sclerosis: a longitudinal study","volume":"64","author":"Fisher","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ana.21423","article-title":"Gray matter atrophy is related to long-term disability in multiple sclerosis","volume":"64","author":"Fisniku","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"8302","DOI":"10.1073\/pnas.0901496106","article-title":"Contactin-2\/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals","volume":"106","author":"Derfuss","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1600-0463.2011.02744.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJMcibr0905482","article-title":"Gray-matter injury in multiple sclerosis","volume":"361","author":"Rudick","year":"2009","journal-title":"N Engl J Med"}],"container-title":["APMIS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0463.2011.02744.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0463.2011.02744.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T02:35:06Z","timestamp":1625538906000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0463.2011.02744.x"}},"subtitle":["CNS PATHOLOGY IN MODELS OF B6 EAE"],"short-title":[],"issued":{"date-parts":[[2011,4,12]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1600-0463.2011.02744.x","relation":{},"ISSN":["0903-4641"],"issn-type":[{"value":"0903-4641","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4,12]]}}}